AstraZeneca's CEO sees 19% pay cut

What does it take to cut a CEO's compensation package by almost 20 percent? Ask David Brennan (photo), head honcho at AstraZeneca. Brennan made 2.15 million pounds ($4.3 million) in 2007, about $2 million of that as base salary and the rest variable compensation. Though his base was set at 5.5 percent higher in 2007 than 2006, his total package dropped by 19 percent because of smaller bonus and decreased reimbursements for relocation expenses. (Brennan moved to the U.K. from the U.S. in January 2006, when he took over as CEO).

Still, Brennan's package didn't drop as much as AstraZeneca's stock did. Shares fell by 21 percent last year. And apparently Brennan is willing to take the hit. According to the blog PharmaGossip, he turned down "an almost double-digit" pay increase for 2008.

- read AstraZeneca's compensation chart for 2007 (pp. 106-107)
- check out the 2006 details (p. 88)
- see Pharma Gossip's item

Related Articles:
Analyst: AZ "worst performer" in pharma. Report
AstraZeneca--Top 8 layoffs of 2007. Report
AstraZeneca lays out road map for recovery. Report 

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Intent-driven audiences are inspired to make health-improving changes after a positive online experience. Find out what they’re driven to do.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.